Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Diabete Type 2, Obesity

In brief

This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.

Key facts

Study ID

NCT06104358

Run by

Rivus Pharmaceuticals, Inc.

People needed

0

Starts

2023-11-17

Expected to finish

2025-03-01

Last updated by the study team

2024-01-09

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to understand the procedures and requirements of the study and provide written informed consent and authorization for protected health information disclosure.
• Willing and able to comply with the requirements of the study protocol.
• Male or female 18 to 70 years of age, inclusive, at time of informed consent.
• Body mass index (BMI) >28.0 kg/m2 and able to fit into the MRI machine.
• Subject has T2D meeting all of the following criteria:

You may not qualify if…

• Body weight >450 pounds.
• Subject-reported history of weight gain or loss >5% in 3 months prior to screening.
• The subject participates in programmed exercise >3 hours per week.

Where it is running

• AdventHealth Translational Research Institute — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.